Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

26.88 -0.37 (-1.35%)
Streaming Delayed Price Updated: 11:13 AM EDT, May 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
23 24 Next >
Eli Lilly, Novo Nordisk Fall As Roche Releases Weight-Loss Drug Data
Roche released early-stage data on its oral weight-loss drug. 
Via Investor's Business Daily
Is Viking Therapeutics the Best Biotech Stock for You?
Let's look beyond the hype the company is generating this year. 
Via The Motley Fool
The 3 Most Undervalued Biotech Stocks to Buy in July 2024
There’s always a strong case for undervalued biotech stocks especially with newer innovation and demand for better treatment. 
Via InvestorPlace
Is Viking Therapeutics Stock Running Out of Steam?
Viking's stock has tripled in less than a year, and its red-hot valuation could have investors thinking twice about buying it today. 
Via The Motley Fool
Better GLP-1 Biotech Stock: Altimmune vs. Viking Therapeutics
Both competitors have promising lead programs, and enough cash, too. 
Via The Motley Fool
Eli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug
Global pharmaceutical company Eli Lilly & Co. (NYSE: LLY) has been in a GLP-1 arms race with its FDA-approved therapies Mounjaro and Zepbound. It's been 
Via MarketBeat
Spotlight on Viking Therapeutics: Analyzing the Surge in Options Activity
Via Benzinga
Here's How Much $1000 Invested In Viking Therapeutics 5 Years Ago Would Be Worth Today
Via Benzinga
Eli Lilly Rose More Than 50% So Far This Year. Can It Soar Past $1,000 in the 2nd Half?
This pharma company is posting double-digit revenue growth. 
Via The Motley Fool
3 Overlooked Giants-in-the-Making for Patient Investors
Consider buying into these overlooked growth stocks for long-term profits that will help to boost a portfolio and deliver riches. 
Via InvestorPlace
The 7 Best Under $10 Stocks to Buy in July 2024
We’re finding big opportunities in some of the best stocks under $10 a share. In fact, here are seven you may want to jump into now. 
Via InvestorPlace
Forget Eli Lilly: 3 Biotech Stocks to Buy Instead
Eli Lilly is a good stock to buy, but these should be even better. 
Via The Motley Fool
Viking Therapeutics Unusual Options Activity For June 25
Via Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth $600 Today
Via Benzinga
S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?
The S&P 500 and Nasdaq 100 indices surged to new all-time highs on Thursday, as investors heightened their expectations for rate cuts following June’s sharply lower-than-expected services sector... 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
3 Biotech Moonshots With Imminent Catalyst Potential
Biotech has been one of the most explosive sectors. Better, further upside is likely, thanks to some of the top biotech stocks with catalysts. 
Via InvestorPlace
Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?
Clinical-state biopharmaceutical company Altimmune Inc. (NASDAQ: ALT) focuses on developing peptide-based therapeutics for obesity and chronic liver diseases 
Via MarketBeat
Exposures Product Safety
Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes
Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy 
Via MarketBeat
Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Global pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound. 
Via MarketBeat
Exposures Product Safety
Viking Therapeutics Stock Is Up by 154% Since January -- Can It Double Again in the Second Half of the Year?
It's a tough act to follow. 
Via The Motley Fool
3 Reasons Why Altimmune Stock Could Be the Next Viking Therapeutics
While their share prices have traveled different paths recently, the similarity between the two companies is striking. 
Via The Motley Fool
The 3 Smartest Biotech Stocks to Buy With $5K Right Now
With global obesity numbers bursting at the seams, some of the smartest biotech stocks to buy are those with weight loss drugs. 
Via InvestorPlace
The Top 3 Weight Loss Drug Stocks to Buy for Huge Gains
Consider buying shares in these pharma companies, each of which is a leader in the weight loss drug sector. 
Via InvestorPlace
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
These healthcare stocks have clear paths to growth over the next few years. 
Via The Motley Fool
Better Growth Stock: Archer Aviation or Viking Therapeutics?
Which one of these potential disruptors is the better buy? 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
The Best Biotech Stock to Invest $1,000 in Right Now
This stock may not be a slam dunk, but it's looking very promising. 
Via The Motley Fool
3 Stocks That Have Soared 179% or More in 2024 and Could Go Even Higher, According to Wall Street
These high-flying stocks could have more room to run if analysts are right. 
Via The Motley Fool
2 Growth Stocks Wall Street Analysts Think Can Soar by at Least 80%
There's a lot of hope for these stocks, but there's also a fair amount of risk. 
Via The Motley Fool
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.